Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Breast 1

Conditions

Breast Neoplasms 48Neoplasm Metastasis 4Hereditary Sensory and Autonomic Neuropathies 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Hyperglycemia 3Multiple Endocrine Neoplasia Type 1 2Advanced Breast Cancer 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pre-menopausal Breast Cancer 1Pancreatic Neoplasms 1Melanoma 1Kidney Neoplasms 1Hormone Receptor Positive Breast Carcinoma 1Head and Neck Neoplasms 1HER2-positive Metastatic Breast Cancer 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Exanthema 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal, Breast 1Anatomic Stage III Breast Cancer AJCC v8 1Advanced or Metastatic ER+ Breast Cancer 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1Advanced HER2+Breast Cancer 1

Interventions

pembrolizumab 19Docetaxel 9atezolizumab 8Cetuximab 8Nivolumab 7cemiplimab 6Ipilimumab 4Immune Checkpoint Inhibitors 4Gemcitabine 4Drug Therapy 4spartalizumab 3palbociclib 3fludarabine 3durvalumab 3avelumab 3Trastuzumab 3Radiotherapy 3Paclitaxel 3Oncolytic Virotherapy 3Irinotecan 3Fulvestrant 3Fluorouracil 3Cyclophosphamide 3Carboplatin 3Bortezomib 3Blood Specimen Collection 3seribantumab 2selpercatinib 2pazopanib 2motexafin gadolinium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Alpelisib × Breast × Clear all
NCT02051751 2020-12-08

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Novartis

Phase 1 Completed
19 enrolled
BreastHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡